Launch week offerEnds in00h00m00s

annual Promonthly Pro

YUKI KOBARI

Has grant

Assistant Professor

Tokyo Women's Medical University

Japan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Japan

About

Yuki Kobari is an Assistant Professor at Tokyo Women's Medical University in Japan. His research primarily focuses on surgical outcomes in cancer treatment, particularly regarding nephrectomy procedures and the efficacy of Enfortumab Vedotin in various patient populations. Recent publications reflect his expertise in the clinical outcomes of renal cell carcinoma and urothelial carcinoma, emphasizing the safety and effectiveness of novel therapies in elderly and hemodialysis patients.

Recent Grants

Grant: Close

造影剤の循環動態に基づく小径腎腫瘍のCT画像解析の開発と臨床応用

Open Date: 2022-04-01

Close Date: 2023-03-31

Articles (11)

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (1)

Hiroki Ishihara

Assistant professor

Tokyo Women's Medical University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

YUKI KOBARI

Research Interests

Make your next move.

Explore related searches

About

Recent Grants

Articles (11)

Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma

CLINICAL OUTCOMES OF REPEAT PARTIAL NEPHRECTOMY COMPARED TO INITIAL PARTIAL NEPHRECTOMY FOR RENAL CELL CARCINOMA: A PROPENSITY SCORE MATCHING STUDY

Comparing surgical outcomes between robot-assisted laparoscopic and open partial nephrectomy for allograft kidney tumors: a retrospective, single-center study

Outcomes of Enfortumab Vedotin Treatment in Patients Ineligible for the EV-301 Trial

Outcomes of Enfortumab Vedotin Treatment in Patients Ineligible for the EV-301 Trial

Safety and efficacy of enfortumab vedotin for locally advanced or metastatic urothelial carcinoma in patients aged 80 years and older: A multicenter retrospective study in Japan

Safety and efficacy of enfortumab vedotin for locally advanced or metastatic urothelial carcinoma in patients aged 80 years and older: A multicenter retrospective study in Japan.

Safety of Enfortumab Vedotin Plus Pembrolizumab in Hemodialysis Patients With Metastatic Urothelial Carcinoma: Case Report

Safety of Enfortumab Vedotin Plus Pembrolizumab in Hemodialysis Patients With Metastatic Urothelial Carcinoma: Case Report

TREATMENT OUTCOMES OF ENFORTUMAB VEDOTIN IN INELIGIBLE PATIENTS FROM THE EV-301 TRIAL

IP24-04 TREATMENT OUTCOMES OF ENFORTUMAB VEDOTIN IN INELIGIBLE PATIENTS FROM THE EV-301 TRIAL

Collaborators (1)

Hiroki Ishihara

Make your next move.